Guanfacine in Children With Tic Disorders

Phase 4

Completed

• Conditions: Tourette Disorder; Tourette Syndrome
• Interventions: Drug: placebo; Drug: extended-release guanfacine (Intuniv)

• Registration Number: NCT01547000
• Lead Sponsor: Yale University

Brief Summary

The goal of this pilot study is to obtain preliminary information on the tolerability and efficacy of extended release guanfacine (trade name Intuniv) in children with Tourette Disorder (TD, also called Tourette syndrome).

Detailed Description

Guanfacine is commonly used for the treatment of tics in children with Tourette Disorder, but neither the immediate release compound nor the new extended release formulation have been evaluated for tics as a primary outcome. This pilot study is not designed to demonstrate efficacy of extended release guanfacine in the treatment of tics in children with TD. Rather, the goal of this trial is to determine whether extended release guanfacine warrants further study in a large scale trial. Immediate-release guanfacine is frequently used in children with TD, but dosing, time to effect and adverse effects with the new extended release guanfacine are unknown. The use of placebo in this trial reduces bias in the measurement of outcomes because it ensures blindness in the parent and clinician ratings.

This is a three-site, investigator-initiated, randomized, double-blind, placebo-controlled, parallel-group study. Subjects who show a positive response to extended release guanfacine in the 8-week double-blind phase will continue on the the drug in an 8-week extension phase. Subjects who are randomly assigned to placebo and do not show improvement will be offered 8-weeks of open-label treatment with Intuniv.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2012-03-01
• Study First Submitted QC: 2012-03-06
• Study First Posted: 2012-03-07
• Study Start: 2012-04
• Primary Completion: 2016-12
• Study Completion: 2016-12
• Results First Submitted: 2018-01-15
• Results First Submitted QC: 2018-05-08
• Results First Posted: 2018-06-08
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-11
• Last Update Posted: 2021-08-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

• Diagnosis of Tourette Disorder or chronic motor or vocal tic disorder.
• Between ages 6 yrs 0 mos and 17 years 0 months.
• Weight >/= 15 kg (33 lbs).
• Ability to swallow pills whole.

Read More

Exclusion Criteria

• IQ < 80.
• Positive pregnancy test.
• Positive drug test.
• Low blood pressure.
• Prior history of hypersensitivity to guanfacine.
• Prior failed treatment with an adequate trial of guanfacine in last 2 years.
• Concurrent treatment with another psychoactive medication for tics, stimulant medication, or Habit Reversal therapy.
• Medication for OCD, anxiety or depression will be allowed if dose is stable for 8 wks with no planned changes; SSRIs are allowed.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Inactive placebo	placebo	-
Extended-release Guanfacine	extended-release guanfacine (Intuniv)	-

Primary Outcome Measures

Name	Time	Method
Yale Global Tic Severity Scale (YGTSS)	8 weeks	The YGTSS is a clinician-rated scale that begins with a systematic inquiry of tic symptoms in the preceding week. Current motor and phonic tics are rated separately according to number, frequency, intensity, complexity, and interference, each rated on 0 to 5 scale with higher scores indicating greater severity/worse outcome (Leckman et al. 1989). The YGTSS yields a total motor score (0-25), a total phonic score (0-25), a total tic score (sum of total motor and total phonic scores; 0-50), and an impairment score (0-50). Higher scores indicate greater severity/worse outcome.

Trial Locations

Locations (3)

University of South Florida; 🇺🇸 Tampa, Florida, United States

Mount Sinai School of Medicine; 🇺🇸 New York, New York, United States

Yale Child Study Center; 🇺🇸 New Haven, Connecticut, United States